These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 30221368)

  • 1. Auxiliary variable-enriched biomarker-stratified design.
    Wang T; Wang X; Zhou H; Cai J; George SL
    Stat Med; 2018 Dec; 37(30):4610-4635. PubMed ID: 30221368
    [TBL] [Abstract][Full Text] [Related]  

  • 2. On Enrichment Strategies for Biomarker Stratified Clinical Trials.
    Wang X; Zhou J; Wang T; George SL
    J Biopharm Stat; 2018; 28(2):292-308. PubMed ID: 28933670
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bayesian two-step Lasso strategy for biomarker selection in personalized medicine development for time-to-event endpoints.
    Gu X; Yin G; Lee JJ
    Contemp Clin Trials; 2013 Nov; 36(2):642-50. PubMed ID: 24075829
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Optimal Bayesian adaptive trials when treatment efficacy depends on biomarkers.
    Zhang Y; Trippa L; Parmigiani G
    Biometrics; 2016 Jun; 72(2):414-21. PubMed ID: 26575199
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relative efficiency of precision medicine designs for clinical trials with predictive biomarkers.
    Shih WJ; Lin Y
    Stat Med; 2018 Feb; 37(5):687-709. PubMed ID: 29205435
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multistage adaptive biomarker-directed targeted design for randomized clinical trials.
    Gao Z; Roy A; Tan M
    Contemp Clin Trials; 2015 May; 42():119-31. PubMed ID: 25778672
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New clinical trial designs in the era of precision medicine: An overview of definitions, strengths, weaknesses, and current use in oncology.
    Janiaud P; Serghiou S; Ioannidis JPA
    Cancer Treat Rev; 2019 Feb; 73():20-30. PubMed ID: 30572165
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Bayesian adaptive design with biomarkers for targeted therapies.
    Eickhoff JC; Kim K; Beach J; Kolesar JM; Gee JR
    Clin Trials; 2010 Oct; 7(5):546-56. PubMed ID: 20571131
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical trial designs for testing biomarker-based personalized therapies.
    Lai TL; Lavori PW; Shih MC; Sikic BI
    Clin Trials; 2012 Apr; 9(2):141-54. PubMed ID: 22397801
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biomarker threshold adaptive designs for survival endpoints.
    Diao G; Dong J; Zeng D; Ke C; Rong A; Ibrahim JG
    J Biopharm Stat; 2018; 28(6):1038-1054. PubMed ID: 29436940
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A subgroup cluster-based Bayesian adaptive design for precision medicine.
    Guo W; Ji Y; Catenacci DVT
    Biometrics; 2017 Jun; 73(2):367-377. PubMed ID: 27775814
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Bayesian adaptive design for biomarker trials with linked treatments.
    Wason JM; Abraham JE; Baird RD; Gournaris I; Vallier AL; Brenton JD; Earl HM; Mander AP
    Br J Cancer; 2015 Sep; 113(5):699-705. PubMed ID: 26263479
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An alternative method to analyse the biomarker-strategy design.
    Kunz CU; Jaki T; Stallard N
    Stat Med; 2018 Dec; 37(30):4636-4651. PubMed ID: 30260533
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bayesian additive decision trees of biomarker by treatment interactions for predictive biomarker detection and subgroup identification.
    Zhao Y; Zheng W; Zhuo DY; Lu Y; Ma X; Liu H; Zeng Z; Laird G
    J Biopharm Stat; 2018; 28(3):534-549. PubMed ID: 29020511
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bayesian adaptive design for targeted therapy development in lung cancer--a step toward personalized medicine.
    Zhou X; Liu S; Kim ES; Herbst RS; Lee JJ
    Clin Trials; 2008; 5(3):181-93. PubMed ID: 18559407
    [TBL] [Abstract][Full Text] [Related]  

  • 16. IBIS: identify biomarker-based subgroups with a Bayesian enrichment design for targeted combination therapy.
    Chen X; Zhang J; Jiang L; Yan F
    BMC Med Res Methodol; 2023 Mar; 23(1):66. PubMed ID: 36941537
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Bayesian adaptive marker-stratified design for molecularly targeted agents with customized hierarchical modeling.
    Zang Y; Guo B; Han Y; Cao S; Zhang C
    Stat Med; 2019 Jul; 38(15):2883-2896. PubMed ID: 30968435
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The use of Bayesian hierarchical models for adaptive randomization in biomarker-driven phase II studies.
    Barry WT; Perou CM; Marcom PK; Carey LA; Ibrahim JG
    J Biopharm Stat; 2015; 25(1):66-88. PubMed ID: 24836519
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Integrating biomarker information within trials to evaluate treatment mechanisms and efficacy for personalised medicine.
    Dunn G; Emsley R; Liu H; Landau S
    Clin Trials; 2013 Oct; 10(5):709-19. PubMed ID: 24000376
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bias in retrospective analyses of biomarker effect using data from an outcome-adaptive randomized trial.
    Ji L; McShane LM; Krailo M; Sposto R
    Clin Trials; 2019 Dec; 16(6):599-609. PubMed ID: 31581815
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.